Pemetor 500 mg/vial
- Generic
- Pemetrexed
- Manufacturer
- Eskayef Pharmaceuticals Ltd.
- Drug class
- Cytotoxic Chemotherapy
- Pregnancy category
- D
Price
৳25,000 per 500 mg vial
Packs & prices
- 500 mg vial৳25,000
This is information only. Do not start, stop or switch medicines without a doctor's advice.
Warnings
Contraindications
Precautions
Side effects
- Myelosuppression
- Renal failure
- Bullous and exfoliative skin toxicity
- Interstitial pneumonitis
- Radiation recall
Pregnancy & lactation
Lactation: Advise women not to breastfeed during treatment with Pemetrexed and for 1 week after the final dose
Drug interactions
More information
Indications
- Initial treatment of patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC) in combination with cisplatin.
- Maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy, as a single agent.
- Treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy, as a single agent.
Dosage
- The recommended dose of Pemetrexed in combination with cisplatin for initial treatment of NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m² as an intravenous infusion over 10 minutes administered prior to cisplatin on Day 1 of each 21-day cycle for up to six cycles in the absence of disease progression or unacceptable toxicity.
- The recommended dose of Pemetrexed for maintenance treatment of NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m² as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity after four cycles of platinum-based first-line chemotherapy.
- The recommended dose of Pemetrexed for treatment of recurrent NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m² as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
Use in children
Pediatric Use: The safety and effectiveness of Pemetrexed in pediatric patients have not been established.
Geriatric Use: Of the 3,946 patients enrolled in clinical studies of Pemetrexed, 34% were 65 and over and 4% were 75 and over. No overall differences in effectiveness were observed between these patients and younger patients. The incidences of Grade 3-4 anemia, fatigue, thrombocytopenia, hypertension, and neutropenia were higher in patients 65 years of age and older as compared to younger patients: in at least one of five randomized clinical trials.
Overdose
Pharmacology
Therapeutic class
Storage
Source: medex.com.bd · Prescribing information (PDF)
Cheaper alternatives
Same generic, strength and form — sorted by price
Pemetrex
Beacon Pharmaceuticals Ltd.
৳25,000 / 500 mg vial
Same price
Alimta
Eli Lilly and Company
৳64,187 / 500 mg vial
৳39,187 more
Bottle/tube prices depend on size — compare quantities before switching.